

# Nicola A Hanania

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8659176/nicola-a-hanania-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264  
papers

12,633  
citations

54  
h-index

105  
g-index

345  
ext. papers

15,109  
ext. citations

4  
avg, IF

6.41  
L-index

#	Paper	IF	Citations
264	Lebrikizumab treatment in adults with asthma. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1088-98	59.2	1213
263	Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. <i>Annals of Internal Medicine</i> , <b>2011</b> , 155, 179-91	8	702
262	Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 804-11	10.2	609
261	Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. <i>Chest</i> , <b>2008</b> , 134, 43S-56S	5.3	455
260	Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 573-82	8	355
259	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 781-796	35.1	302
258	Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. <i>Radiology</i> , <b>2011</b> , 261, 274-82	20.5	300
257	Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. <i>Thorax</i> , <b>2015</b> , 70, 748-56	7.3	291
256	The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. <i>Chest</i> , <b>2003</b> , 124, 834-43	5.3	283
255	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. <i>Lancet Respiratory Medicine</i> , <b>2013</b> , 1, 210-23	35.1	249
254	Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 132, 1295-302	11.5	224
253	Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 604-11	10.2	202
252	Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. <i>Clinical and Experimental Allergy</i> , <b>2017</b> , 47, 161-175	4.1	199
251	Adverse effects of inhaled corticosteroids. <i>American Journal of Medicine</i> , <b>1995</b> , 98, 196-208	2.4	195
250	Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. <i>Chest</i> , <b>1994</b> , 105, 111-6	5.3	190
249	Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. <i>Chest</i> , <b>2015</b> , 147, 894-942	5.3	169
248	Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , <b>1995</b> , 96, 571-9	11.5	149

247	Radiation-Induced Lung Injury: Assessment and Management. <i>Chest</i> , <b>2019</b> , 156, 150-162	5.3	145
246	Omalizumab in asthma: an update on recent developments. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2014</b> , 2, 525-36.e1	5.4	145
245	Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 324-330	10.2	140
244	The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. <i>Respiratory Medicine</i> , <b>2012</b> , 106, 319-28	4.6	126
243	A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2012</b> , 9, 151-9	2	114
242	Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 129, 1252-1258.e1	11.5	112
241	The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2008</b> , 21, 134-41	3.5	102
240	Beta-agonist intrinsic efficacy: measurement and clinical significance. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 165, 1353-8	10.2	99
239	Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 27-34	4.7	98
238	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 2037-2047.e10	11.5	95
237	Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 2435-40	11.5	92
236	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 1000-1010	9.3	90
235	Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. <i>Therapeutic Advances in Chronic Disease</i> , <b>2014</b> , 5, 212-27	4.9	86
234	The efficacy and safety of the novel long-acting $\beta_2$ agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. <i>Chest</i> , <b>2012</b> , 142, 119-127	5.3	83
233	Periostin, a novel biomarker of TH2-driven asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2014</b> , 20, 60-5		77
232	Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. <i>Leukemia and Lymphoma</i> , <b>2002</b> , 43, 423-6	1.9	76
231	Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2011</b> , 107, 65-70	3.2	73
230	Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. <i>Journal of Allergy and Clinical Immunology</i> , <b>2004</b> , 113, 717-24	11.5	70

229	Predicting episodes of poor asthma control in treated patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2006</b> , 118, 1226-33	11.5	69
228	Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. <i>Respiratory Medicine</i> , <b>2012</b> , 106, 91-101	4.6	67
227	Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. <i>Chest</i> , <b>2017</b> , 151, 68-77	5.3	66
226	COVID-19, asthma, and biological therapies: What we need to know. <i>World Allergy Organization Journal</i> , <b>2020</b> , 13, 100126	5.2	64
225	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. <i>PLoS Genetics</i> , <b>2016</b> , 12, e1006011	6	64
224	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 552-563	2	61
223	Targeting airway inflammation in asthma: current and future therapies. <i>Chest</i> , <b>2008</b> , 133, 989-98	5.3	61
222	COPDGene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2019</b> , 6, 384-399	2.7	61
221	Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 516-526	5.4	61
220	Bronchodilator reversibility in COPD. <i>Chest</i> , <b>2011</b> , 140, 1055-1063	5.3	60
219	Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 1397-1405	10.2	59
218	Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2011</b> , 8, 293-9	2	59
217	Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension Delivery Technology in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , <b>2017</b> , 126, 105-115	4.6	58
216	Factors associated with emergency department dependence of patients with asthma. <i>Chest</i> , <b>1997</b> , 111, 290-5	5.3	58
215	An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly. <i>Annals of the American Thoracic Society</i> , <b>2016</b> , 13, 2064-2077	4.7	57
214	Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. <i>Respiratory Research</i> , <b>2011</b> , 12, 6	7.3	57
213	Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 1516-22	4.6	56
212	Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 261-78	3.5	54

211	Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. <i>Proceedings of the American Thoracic Society</i> , <b>2007</b> , 4, 526-34		53
210	Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 69-84	35.1	53
209	Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 12623-32	5.4	51
208	Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). <i>Respiratory Medicine</i> , <b>2010</b> , 104, 1160-70	4.6	49
207	EAACI Biologicals Guidelines-Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 14-44	9.3	48
206	Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2007</b> , 36, 254-61	5.7	47
205	Role of T2 inflammation biomarkers in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2016</b> , 22, 59-68	3	47
204	The asthma COPD overlap syndrome (ACOS). <i>Current Allergy and Asthma Reports</i> , <b>2015</b> , 15, 509	5.6	46
203	Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. <i>Chest</i> , <b>2015</b> , 147, 883-893	5.3	44
202	A simplified score to quantify comorbidity in COPD. <i>PLoS ONE</i> , <b>2014</b> , 9, e114438	3.7	44
201	Accidental hypothermia. <i>Critical Care Clinics</i> , <b>1999</b> , 15, 235-49	4.5	44
200	Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. <i>International Journal of COPD</i> , <b>2010</b> , 5, 1-10	3	43
199	Racial differences in quality of life in patients with COPD. <i>Chest</i> , <b>2011</b> , 140, 1169-1176	5.3	42
198	Targeting IgE in asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2012</b> , 18, 1-5	3	42
197	COPD in the elderly patient. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2010</b> , 31, 596-606	3.9	41
196	A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. <i>American Journal of Emergency Medicine</i> , <b>2006</b> , 24, 259-67	2.9	41
195	The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2008</b> , 21, 540-50	3.5	40
194	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 1043-1057	9.3	39

193	Age-related differences in asthma outcomes in the United States, 1988-2006. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2013</b> , 110, 240-6, 246.e1	3.2	39
192	The safety of long-acting $\beta_2$ -agonists in the treatment of stable chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , <b>2013</b> , 8, 53-64	3	39
191	Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. <i>Current Opinion in Pulmonary Medicine</i> , <b>2010</b> , 16, 1-5	3	39
190	Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. <i>Chest</i> , <b>2016</b> , 149, 916-26	5.3	38
189	The accuracy of a handheld portable spirometer. <i>Chest</i> , <b>1996</b> , 109, 152-7	5.3	38
188	Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary disease. <i>Metabolism: Clinical and Experimental</i> , <b>2011</b> , 60, 1449-55	12.7	37
187	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 1058-1068	9.3	36
186	beta-Adrenoceptor inverse agonists in asthma. <i>Current Opinion in Pharmacology</i> , <b>2010</b> , 10, 254-9	5.1	36
185	Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. <i>International Journal of COPD</i> , <b>2019</b> , 14, 1127-1138	3	35
184	Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. <i>Current Opinion in Pulmonary Medicine</i> , <b>2018</b> , 24, 50-55	3	35
183	Predictive Biomarkers for Asthma Therapy. <i>Current Allergy and Asthma Reports</i> , <b>2017</b> , 17, 69	5.6	35
182	A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges. <i>International Journal of COPD</i> , <b>2015</b> , 10, 725-38	3	35
181	Asthma in the elderly: current knowledge and future directions. <i>Current Opinion in Pulmonary Medicine</i> , <b>2010</b> , 16, 55-9	3	35
180	Acute asthma in pregnancy. <i>Critical Care Medicine</i> , <b>2005</b> , 33, S319-24	1.4	35
179	One hundred years of chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , <b>2007</b> , 101, 1049-65	4.6	34
178	Anti-inflammatory activities of beta2-agonists. <i>Inflammation and Allergy: Drug Targets</i> , <b>2004</b> , 3, 271-7		34
177	Trends in 30-day readmission rates after COPD hospitalization, 2006-2012. <i>Respiratory Medicine</i> , <b>2017</b> , 130, 92-97	4.6	33
176	Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2008</b> , 5, 25-34	2	33

175	Asthma in older adults. <i>Clinics in Chest Medicine</i> , <b>2007</b> , 28, 685-702, v	5.3	33
174	and its IgE-inducing enterotoxins in asthma: current knowledge. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	32
173	Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2014</b> , 1, 105-114	2.7	32
172	Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , <b>2017</b> , 23, 696-704	2.4	31
171	Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. <i>Cleveland Clinic Journal of Medicine</i> , <b>2018</b> , 85, S11-S18	2.8	31
170	Clinical Epidemiology of COPD: Insights From 10 Years of the COPD Gene Study. <i>Chest</i> , <b>2019</b> , 156, 228-238	3.3	29
169	Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. <i>Drug Safety</i> , <b>2018</b> , 41, 489-509	5.1	28
168	Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. <i>Health and Quality of Life Outcomes</i> , <b>2012</b> , 10, 100	3	28
167	Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. <i>Drugs</i> , <b>2009</b> , 69, 1205-16	12.1	28
166	Acute asthma in pregnancy. <i>Critical Care Clinics</i> , <b>2004</b> , 20, 731-45, x	4.5	28
165	Racial differences in CT phenotypes in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2013</b> , 10, 20-7	2	27
164	Ten years of tiotropium: clinical impact and patient perspectives. <i>International Journal of COPD</i> , <b>2013</b> , 8, 117-25	3	27
163	Comparative effectiveness of noninvasive ventilation vs invasive mechanical ventilation in chronic obstructive pulmonary disease patients with acute respiratory failure. <i>Journal of Hospital Medicine</i> , <b>2013</b> , 8, 165-72	2.7	27
162	Gender differences of airway dimensions in anatomically matched sites on CT in smokers. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2011</b> , 8, 285-92	2	27
161	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , <b>2016</b> , 13, 1016-25	4.7	27
160	Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1629-1633.e2	11.5	27
159	Clinical Approach to the Therapy of Asthma-COPD Overlap. <i>Chest</i> , <b>2019</b> , 155, 168-177	5.3	26
158	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , <b>2020</b> , 6, 47-66	3	26



157	Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 1025-1031.e2	5.4	25
156	The Role of Inhalation Delivery Devices in COPD: Perspectives of Patients and Health Care Providers. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2018</b> , 5, 111-123	2.7	25
155	Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPD Gene and SPIROMICS Cohorts. <i>Chest</i> , <b>2016</b> , 149, 927-35	5.3	25
154	Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression. <i>Chest</i> , <b>2018</b> , 153, 65-76	5.3	23
153	The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. <i>Respiratory Medicine</i> , <b>2007</b> , 101, 1007-14	4.6	23
152	Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. <i>Journal of Applied Physiology</i> , <b>2012</b> , 112, 42-7	3.7	22
151	The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 531-42	3.5	22
150	Cognitive-behavioral therapy for chronic cardiopulmonary conditions: preliminary outcomes from an open trial. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , <b>2010</b> , 12,		22
149	Validity and Responsiveness of the Depression Anxiety Stress Scales-21 (DASS-21) in COPD. <i>Chest</i> , <b>2019</b> , 155, 1166-1177	5.3	22
148	Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 366-75	4.6	21
147	Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?. <i>Current Opinion in Pulmonary Medicine</i> , <b>2017</b> , 23, 3-11	3	21
146	Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2013</b> , 10, 482-92	2	21
145	Treatments for COPD. <i>Respiratory Medicine</i> , <b>2005</b> , 99 Suppl B, S28-40	4.6	21
144	Test Performance Characteristics of the AIR, GAD-7, and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, 926-934	4.7	20
143	One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. <i>Chest</i> , <b>2014</b> , 146, 1531-1542	5.3	20
142	Effect of a primary care continuing education program on clinical practice of chronic obstructive pulmonary disease: translating theory into practice. <i>Mayo Clinic Proceedings</i> , <b>2012</b> , 87, 862-70	6.4	20
141	Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients. <i>Chest</i> , <b>1998</b> , 114, 752-6	5.3	20
140	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 294-302	10.2	20



139	The St. George's Respiratory Questionnaire Definition of Chronic Bronchitis May Be a Better Predictor of COPD Exacerbations Compared With the Classic Definition. <i>Chest</i> , <b>2019</b> , 156, 685-695	5.3	19
138	Budesonide/formoterol combination in COPD: a US perspective. <i>International Journal of COPD</i> , <b>2010</b> , 5, 357-66	3	19
137	The safety and efficacy of arformoterol and formoterol in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2010</b> , 7, 17-31	2	19
136	Vasodilators in mechanical ventilation. <i>Critical Care Clinics</i> , <b>1998</b> , 14, 611-27	4.5	19
135	Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. <i>Intensive Care Medicine</i> , <b>2021</b> , 47, 1258-1270	14.5	19
134	Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 826-835	4.7	18
133	Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. <i>Respiratory Care</i> , <b>2018</b> , 63, 833-839	2.1	18
132	Ventilation of patients with asthma and obstructive lung disease. <i>Critical Care Clinics</i> , <b>1998</b> , 14, 685-705	4.5	18
131	Targeting IL-5 in COPD. <i>International Journal of COPD</i> , <b>2019</b> , 14, 1045-1051	3	17
130	Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2020</b> , 125, 565-576.e1	3.2	17
129	Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2018</b> , 120, 414-418.e1	3.2	17
128	New bronchodilators. <i>Current Opinion in Pharmacology</i> , <b>2012</b> , 12, 238-45	5.1	17
127	Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2008</b> , 2, 199-208	4.9	17
126	Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. <i>Current Opinion in Internal Medicine</i> , <b>2005</b> , 11, 129-34		17
125	Implications of Marijuana Decriminalization on the Practice of Pulmonary, Critical Care, and Sleep Medicine. A Report of the American Thoracic Society Marijuana Workgroup. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 1700-10	4.7	16
124	A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. <i>Chest</i> , <b>2011</b> , 140, 565-566	5.3	16
123	The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. <i>Chest</i> , <b>2016</b> , 150, 188-95	5.3	16
122	Immunological biomarkers in severe asthma. <i>Seminars in Immunology</i> , <b>2019</b> , 46, 101332	10.7	16

121	The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. <i>Journal of the American Medical Directors Association</i> , <b>2017</b> , 18, 955-959.e6	5.9	15
120	Prevalence of airway obstruction assessed by lung function questionnaire. <i>Mayo Clinic Proceedings</i> , <b>2011</b> , 86, 375-81	6.4	15
119	Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. <i>Clinical Therapeutics</i> , <b>2008</b> , 30 Spec No, 989-1002	3.5	15
118	The Hospital Readmissions Reduction Program and Readmissions for Chronic Obstructive Pulmonary Disease, 2006-2015. <i>Annals of the American Thoracic Society</i> , <b>2020</b> , 17, 450-456	4.7	15
117	Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 53, 20-26	3.5	15
116	Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , <b>2017</b> , 30, 256-266	3.8	14
115	Antifungals in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2015</b> , 21, 48-54	3	14
114	Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 133, AB402	11.5	14
113	Health-care utilization after near-fatal asthma. <i>Chest</i> , <b>1995</b> , 107, 1564-9	5.3	14
112	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , <b>2019</b> , 154, 86-92	4.6	13
111	How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 435-446	5.5	13
110	Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 633-643.e1	5.4	13
109	Assessing biomarkers in a real-world severe asthma study (ARIETTA). <i>Respiratory Medicine</i> , <b>2016</b> , 115, 7-12	4.6	13
108	IgE-mediated asthma: New revelations and future insights. <i>Respiratory Medicine</i> , <b>2016</b> , 112, 128-9	4.6	13
107	Measuring the impact of a live, case-based, multiformat, interactive continuing medical education program on improving clinician knowledge and competency in evidence-based COPD care. <i>International Journal of COPD</i> , <b>2011</b> , 6, 297-307	3	13
106	Safety of chronic obstructive pulmonary disease medications: a primary care perspective. <i>Postgraduate Medicine</i> , <b>2011</b> , 123, 72-9	3.7	13
105	Evaluation of obstructive lung disease with vibration response imaging. <i>Journal of Asthma</i> , <b>2008</b> , 45, 923-30	1.9	13
104	Pulmonary-renal syndromes in the intensive care unit. <i>Critical Care Clinics</i> , <b>2002</b> , 18, 881-95, x	4.5	13

103	Obesity modulates diaphragm curvature in subjects with and without COPD. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2017</b> , 313, R620-R629	3.2	12
102	Characteristics and outcomes of older adults with long-standing versus late-onset asthma. <i>Journal of Asthma</i> , <b>2017</b> , 54, 223-229	1.9	12
101	Biological treatments for severe asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , <b>2019</b> , 19, 379-386	3.3	12
100	Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - A cross sectional analysis of the COPDGene cohort. <i>Journal of Psychosomatic Research</i> , <b>2019</b> , 118, 18-26	4.1	12
99	The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD. <i>International Journal of COPD</i> , <b>2006</b> , 1, 345-54	3	11
98	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. <i>American Journal of Kidney Diseases</i> , <b>2020</b> , 75, 935-945	7.4	10
97	Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. <i>Thorax</i> , <b>2020</b> , 75, 735-743	7.3	10
96	A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 1310-20	4.6	10
95	Hospital management of acute exacerbations of chronic obstructive pulmonary disease. <i>Journal of Hospital Medicine</i> , <b>2015</b> , 10, 328-39	2.7	10
94	Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps. <i>Current Opinion in Pulmonary Medicine</i> , <b>2021</b> , 27, 45-53	3	10
93	The many faces of asthma-chronic obstructive pulmonary disease overlap. <i>Current Opinion in Pulmonary Medicine</i> , <b>2019</b> , 25, 1-10	3	9
92	Targeting lipid mediators in asthma: time for reappraisal. <i>Current Opinion in Pulmonary Medicine</i> , <b>2019</b> , 25, 121-127	3	9
91	Controversies and opportunities in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2018</b> , 24, 83-93		9
90	COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. <i>Journal of Family Practice</i> , <b>2018</b> , 67, S11-S18	0.2	9
89	Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and -Acetylcysteine) Supplementation.. <i>Antioxidants</i> , <b>2021</b> , 11,	7.1	9
88	Optimizing safety of COPD treatments: role of the nurse practitioner. <i>Journal of Multidisciplinary Healthcare</i> , <b>2013</b> , 6, 53-63	2.8	8
87	Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 2121-33	3.5	8
86	How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 1081-1088	5.4	8

85	Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 2630-2639.e6	5.4	7
84	Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. <i>Advances in Therapy</i> , <b>2009</b> , 26, 1024-34	4.1	7
83	Update on the pharmacologic therapy for chronic obstructive pulmonary disease. <i>Clinics in Chest Medicine</i> , <b>2007</b> , 28, 589-607, vi-vii	5.3	7
82	Revisiting asthma control: how should it best be defined?. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2007</b> , 20, 483-92	3.5	7
81	Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. <i>Expert Review of Respiratory Medicine</i> , <b>2016</b> , 10, 767-80	3.8	7
80	Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 507-515.e10	5.4	7
79	Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. <i>Respiratory Care</i> , <b>2018</b> , 63, 840-848	2.1	7
78	Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, AB97	11.5	6
77	Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, AB97	11.5	6
76	Role of anticholinergics in asthma management: recent evidence and future needs. <i>Current Opinion in Pulmonary Medicine</i> , <b>2015</b> , 21, 103-8	3	6
75	Measuring Competence in Metered Dose Inhaler Use Using Capmedic Electronic Inhaler Monitoring Tool. <i>Chest</i> , <b>2016</b> , 150, 14A	5.3	6
74	It's about time--directing our attention toward modifying the course of COPD. <i>Respiratory Medicine</i> , <b>2008</b> , 102 Suppl 1, S37-48	4.6	6
73	Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2016</b> , 4, 7-20	2.7	6
72	Precision medicine and treatable traits in chronic airway diseases - where do we stand?. <i>Current Opinion in Pulmonary Medicine</i> , <b>2020</b> , 26, 33-39	3	6
71	Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma. <i>ClinicoEconomics and Outcomes Research</i> , <b>2019</b> , 11, 301-307	1.7	5
70	Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , <b>2016</b> , 111, 30-8	4.6	5
69	Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. <i>Journal of the American Medical Association</i> , <b>2017</b> , 18, 1063-1068	5.9	5
68	Arformoterol tartrate in the treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , <b>2010</b> , 4, 155-62	3.8	5

67	The Rational Use of $\beta_2$ -Agonists in the Management of Asthma: Maintenance, Rescue, and Emergency. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>1998</b> , 19, 613-624	3.9	5
66	Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension $\square$ Delivery Technology Versus Foradil $\square$ Aerolizer $\square$ in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , <b>2016</b> , 4, 21-33	2.7	5
65	Bayesian inference of networks across multiple sample groups and data types. <i>Biostatistics</i> , <b>2020</b> , 21, 561-576	3.7	5
64	Long-Term Benefits of Pulmonary Rehabilitation in Patients With COPD: A 2-Year Follow-Up Study. <i>Chest</i> , <b>2021</b> , 159, 967-974	5.3	5
63	New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. <i>International Journal of COPD</i> , <b>2018</b> , 13, 2805-2819	3	5
62	Asthma outcomes revisited. <i>Current Opinion in Pulmonary Medicine</i> , <b>2013</b> , 19, 6-12	3	4
61	Evaluating the safety of COPD medications: an evidence-based review. <i>Chest</i> , <b>2013</b> , 144, 1357-1367	5.3	4
60	The impact of fungal allergic sensitization on asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2021</b> , 27, 3-8	3	4
59	Lebrikizumab in the treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 847-852	5.4	4
58	Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 153-159	3.8	4
57	Factors associated with depressive symptoms in uncontrolled asthmatics. <i>Journal of Asthma</i> , <b>2018</b> , 55, 555-560	1.9	4
56	Assessing Patient and Provider Perceptions of Factors Associated with Patient Engagement in Asthma Care. <i>Annals of the American Thoracic Society</i> , <b>2017</b> , 14, 659-666	4.7	3
55	Novel therapeutic targets and drug development for the precision treatment of COPD. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2019</b> , 4, 121-128	1.6	3
54	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	3
53	Determinants of lung function improvement with omalizumab in adults with allergic asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 2068-2070	5.4	3
52	One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD)Republished article. <i>Respiratory Medicine: COPD Update</i> , <b>2008</b> , 4, 8-25		3
51	Influenza vaccine in patients with asthma. <i>Expert Review of Vaccines</i> , <b>2006</b> , 5, 111-8	5.2	3
50	A Risk Prediction Model for Mortality Among Smokers in the COPDGene $\square$ Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , <b>2020</b> , 7, 346-361	2.7	3

49	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. <i>Journal of Inflammation</i> , <b>2021</b> , 18, 17	6.7	3
48	Confronting the Challenge of COPD: What Is New in the Approaches to Diagnosis, Treatment, and Patient Outcomes. <i>Chest</i> , <b>2018</b> , 154, 984-985	5.3	3
47	Association of Triglyceride-Glucose Index and Lung Health: A Population-Based Study. <i>Chest</i> , <b>2021</b> , 160, 1026-1034	5.3	3
46	Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD. <i>International Journal of COPD</i> , <b>2021</b> , 16, 2515-2522	3	3
45	Management of Life-Threatening Asthma: Severe Asthma Series.. <i>Chest</i> , <b>2022</b> ,	5.3	3
44	Safety of inhaled long-acting anti-muscarinic agents in COPD. <i>Postgraduate Medicine</i> , <b>2017</b> , 129, 500-512;7	3.7	2
43	Design of a home-based intervention for Houston-area African-American adults with asthma: Methods and lessons learned from a pragmatic randomized trial. <i>Contemporary Clinical Trials</i> , <b>2020</b> , 91, 105977	2.3	2
42	Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, AB13	11.5	2
41	Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. <i>International Journal of COPD</i> , <b>2018</b> , 13, 499-508	3	2
40	The responsiveness of the Manchester Chronic Obstructive Pulmonary Disease Fatigue Scale to pulmonary rehabilitation. <i>Therapeutic Advances in Chronic Disease</i> , <b>2019</b> , 10, 2040622319882206	4.9	2
39	Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. <i>Expert Opinion on Emerging Drugs</i> , <b>2017</b> , 22, 285-299	3.7	2
38	The Saudi guidelines for chronic obstructive pulmonary disease: A fresh "Real-World" approach to COPD. <i>Annals of Thoracic Medicine</i> , <b>2014</b> , 9, 53-4	2.2	2
37	Differentiating Asthma and COPD Patients. <i>Chest</i> , <b>2004</b> , 126, 654-655	5.3	2
36	Medical Personnel Knowledge of the Ability to Use Inhaling Devices. <i>Chest</i> , <b>1995</b> , 107, 290	5.3	2
35	Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 3474-3481	5.4	2
34	DUPILUMAB REDUCES SEVERE ASTHMA EXACERBATION RATE AND IMPROVES LUNG FUNCTION REGARDLESS OF AGE AT ONSET OF ASTHMA: THE LIBERTY ASTHMA QUEST STUDY. <i>Chest</i> , <b>2019</b> , 156, A936-A939	5.3	2
33	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. <i>Chest</i> , <b>2021</b> , 159, 985-995	5.3	2
32	Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> ,	5.4	2



31	The challenge of differentiating asthma from chronic obstructive pulmonary disease. <i>Managed Care</i> , <b>2005</b> , 14, 9-15; discussion 24-6	0.3	2
30	Depressive and anxiety symptoms in patients with COPD: A network analysis.. <i>Respiratory Medicine</i> , <b>2022</b> , 198, 106865	4.6	2
29	Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 1430-1436	5.4	1
28	A Better Way to Assess Bronchoreversibility: Response. <i>Chest</i> , <b>2012</b> , 141, 1118-1119	5.3	1
27	Inhaled Salmeterol/Fluticasone Propionate Combination in Chronic Obstructive Pulmonary Disease. <i>Treatments in Respiratory Medicine</i> , <b>2002</b> , 1, 283-283		1
26	Biologics targeting type 2 inflammation in severe asthma <b>2019</b> , 285-303		1
25	Revisiting Late-Onset Asthma: Clinical Characteristics and Association with Allergy. <i>Journal of Asthma and Allergy</i> , <b>2020</b> , 13, 743-752	3.1	1
24	Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. <i>International Journal of COPD</i> , <b>2021</b> , 16, 865-875	3	1
23	Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. <i>Respiratory Medicine</i> , <b>2021</b> , 176, 106278	4.6	1
22	Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. <i>International Journal of COPD</i> , <b>2019</b> , 14, 117-127	3	1
21	Clinically Significant and Comorbid Anxiety and Depressive Symptoms Predict Severe Respiratory Exacerbations in Smokers: A Post-Hoc Analysis of the COPD Gene and SPIROMICS Cohorts. <i>Annals of the American Thoracic Society</i> , <b>2021</b> ,	4.7	1
20	Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home. <i>International Journal of COPD</i> , <b>2021</b> , 16, 2687-2695	3	1
19	Revisiting Mild Asthma: Current Knowledge and Future Needs. <i>Chest</i> , <b>2021</b> ,	5.3	1
18	Eosinophilic vs. Neutrophilic Asthma. <i>Current Pulmonology Reports</i> , <b>2020</b> , 9, 28-35	0.5	0
17	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. <i>Journal of Asthma</i> , <b>2021</b> , 58, 849-854	1.9	0
16	Optimizing care of your patients with COPD. <i>Nursing (Auckland, N Z)</i> , <b>2014</b> , 7	1	
15	Pharmacological Therapy: Bronchodilators <b>2011</b> , 99-114		
14	The COPD Pipeline XII. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2011</b> , 8, 387-91	2	

- 13 Bronchodilators: Beta2-Agonists and Anticholinergics **2008**, 241-250
- 12 Ipratropium Bromide HFA. *Treatments in Respiratory Medicine*, **2005**, 4, 221-222
- 11 Novel and Alternative Therapies for Asthma in Older Adults **2019**, 135-153
- 10 Practical Considerations in Management of Allergic Asthma. *Respiratory Medicine*, **2020**, 155-180 0.2
- 9 Asthma and Aging **2016**, 397-428
- 8 Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS) During Pregnancy 338-347
- 7 Th2 lymphocyte potassium channels in asthma. *FASEB Journal*, **2011**, 25, 945.7 0.9
- 6 Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. *International Journal of COPD*, **2021**, 16, 1925-1938 3
- 5 Response. *Chest*, **2019**, 156, 1276 5.3
- 4 Severe Acute Asthma **2018**, 391-402
- 3 COPD Management in the Primary Care Setting. *Journal of Family Practice*, **2018**, 67, S27-S32 0.2
- 2 The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety.. *Respiratory Medicine*, **2022**, 197, 106850<sup>4.6</sup>
- 1 Managing hospitalized patients with a COPD exacerbation: the role of hospitalists and the multidisciplinary team.. *Postgraduate Medicine*, **2021**, 1-8 3.7